About Us

BioAtla© develops novel therapies with improved therapeutic index that have the potential to revolutionize cancer treatment.

BioAtla© is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow us to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.

We have assembled a world class team

We are looking for exceptional candidates dedicated to our corporate values and excited about our mission of developing the next generation of cancer drugs.